<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-five patients, 16 men and 9 women, 5-59 years of age with the <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> and cardiac complications were started on <z:chebi fb="2" ids="8499">propranolol</z:chebi> over a 6-year period </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="2" ids="8499">Propranolol</z:chebi> was used as a beta-adrenergic blocking agent to reduce myocardial contractility in an attempt thereby to stay the progression of <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo> and to prevent <z:hpo ids='HP_0011009'>acute</z:hpo> dissection of the aorta </plain></SENT>
<SENT sid="2" pm="."><plain>The indications for prophylactic treatment were <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo>, with <z:hpo ids='HP_0001659'>aortic regurgitation</z:hpo> in most cases </plain></SENT>
<SENT sid="3" pm="."><plain>It was intended to keep the pulse rate below 70 at <z:hpo ids='HP_0000001'>all</z:hpo> times or below 60 at rest </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="2" ids="8499">Propranolol</z:chebi> given in daily doses of 120-160 mg caused no side effects </plain></SENT>
<SENT sid="5" pm="."><plain>The mean observation time for <z:chebi fb="2" ids="8499">propranolol</z:chebi> treatment in the 25 patients was 3.0 +/- 1.8 years ranging from 1-7 years </plain></SENT>
<SENT sid="6" pm="."><plain>In spite of treatment, 5 patients (1 female and 4 males) experienced <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002647'>aortic dissection</z:hpo> of rupture with fatal outcome </plain></SENT>
<SENT sid="7" pm="."><plain>This occurred in 2 patients with the asthenic type, in 2 patients with the nonasthenic type, and in 1 patient with the <z:e sem="disease" ids="C0268365" disease_type="Disease or Syndrome" abbrv="">marfanoid hypermobility syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Serial echocardiograms showed that other patients on <z:chebi fb="2" ids="8499">propranolol</z:chebi> developed increasing <z:mpath ids='MPATH_66'>dilatation</z:mpath> of the aortic root </plain></SENT>
<SENT sid="9" pm="."><plain>These observations indicate that <z:chebi fb="2" ids="8499">propranolol</z:chebi> does not necessarily protect against <z:hpo ids='HP_0002647'>aortic dissection</z:hpo> nor stop the progression of the <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo> when cystic medial <z:mp ids='MP_0001651'>necrosis</z:mp> of the aorta is already present </plain></SENT>
</text></document>